Published: The New England Journal of Medicine
Date:
Authors: Aaron S Kelly 1 , Pernille Auerbach 1 , Margarita Barrientos-Perez 1 , Inge Gies 1 , Paula M Hale 1 , Claude Marcus 1 , Lucy D Mastrandrea 1 , Nandana Prabhu 1 , Silva Arslanian 1 , NN8022-4180 Trial Investigators
Abstract:
Background: Obesity is a chronic disease with limited treatment options in pediatric patients. Liraglutide may be useful for weight management in adolescents with obesity.
Published: Primary Care Diabetes
Date:
Authors: Juan Pablo González-Rivas 1 , William Polonsky 2 , María María Infante-García 3 , Maritza Duran 4 , Eunice Ugel 5 , María Ines Marulanda 6 , Jeffrey I Mechanick 7 , Ramfis Nieto-Martínez 8
Abstract:
Evidence suggests that depression is more common in patients with diabetes than in the general population. However, contradictory results expose controversy in this association.
Published: The New England Journal of Medicine
Date:
Authors: William V Tamborlane, Margarita Barrientos-Pérez, Udi Fainberg, Helle Frimer-Larsen, Mona Hafez, Paula M Hale, Muhammad Y Jalaludin, Margarita Kovarenko, Ingrid Libman, Jane L Lynch, Paturi Rao, Naim Shehadeh, Serap Turan, Daniel Weghuber, Timothy Barrett, Ellipse Trial Investigators
Abstract:
Metformin is the regulatory-approved treatment of choice for most youth with type 2 diabetes early in the disease. However, early loss of glycemic control has been observed with metformin monotherapy. Whether liraglutide added to metformin (with or without basal insulin treatment) is safe and effective in youth with type 2 diabetes is unknown.
Published: Endocrine Practice
Date:
Authors: Ramfis Nieto-Martínez, Juan P González-Rivas, Eunice Ugel, Imperia Brajkovich, Alejandro Risquez, W Timothy Garvey, Jeffrey I Mechanick
Abstract:
To determine the prevalence of obesity according to the American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) framework based on a complications-centric model with further application of the Cardiometabolic Disease Staging (CMDS) system in a Venezuelan population.
Published: American Journal of Nephrology
Date:
Authors: Meg J Jardine 1 2 , Kenneth W Mahaffey 3 , Bruce Neal 1 4 5 6 , Rajiv Agarwal 7 , George L Bakris 8 , Barry M Brenner 9 , Scott Bull 10 , Christopher P Cannon 11 , David M Charytan 12 , Dick de Zeeuw 13 , Robert Edwards 10 , Tom Greene 14 , Hiddo J L Heerspink 13 , Adeera Levin 15 , Carol Pollock 16 , David C Wheeler 17 , John Xie 10 , Hong Zhang 18 , Bernard Zinman 19 , Mehul Desai 10 , Vlado Perkovic 1 , CREDENCE study investigators
Abstract:
People with diabetes and kidney disease have a high risk of cardiovascular events and progression of kidney disease. Sodium glucose co-transporter 2 inhibitors lower plasma glucose by reducing the uptake of filtered glucose in the kidney tubule, leading to increased urinary glucose excretion.
Published: Pan American Journal of Public Health
Date:
Authors: Patricio López-Jaramillo 1 , Ramfis E Nieto-Martínez 2 , Gestne Aure-Fariñez 3 , Carlos O Mendivil 4 , Rodolfo A Lahsen 5 , Ruy L Silva-Filho 6 , Luiz A Andreotti 7 , Mónica E Manrique 8 , Miguel A Pasquel-Andrade 9 , Ignacio Rangel 10 , Maricela Vidrio 11 , Rutila Castañeda 12 , Manuela Restrepo 13 , Miguel E Pinto 14
Abstract:
To understand the status of prediabetes diagnosis and treatment in Latin America and to evaluate the use of metformin for diabetes prevention in this context.
Published: Current Diabetes Reports
Date:
Authors: Ramfis Nieto-Martínez 1 2 3 , Juan P González-Rivas 4 , José R Medina-Inojosa 5 , Hermes Florez 6 7
Abstract:
Eating disorders (ED) affect energy intake modifying body fat depots. Prior evidence suggests that binge eating disorder (BED) and bulimia nervosa (BN) could increase the risk for type 2 diabetes (T2D), while anorexia nervosa (AN) could reduce it.
Published: Annals of Global Health
Date:
Authors: Ramfis Nieto-Martínez 1 , Juan P González-Rivas 2 , Pablo Aschner 3 , Noël C Barengo 4 , Jeffrey I Mechanick 5
Abstract:
Type 2 diabetes (T2D) imposes a heavy burden in developing countries, requiring effective primary prevention policies. Randomized clinical trials have identified successful strategies in T2D prevention. However, translating these results to real-life scenarios and adapting to ethnocultural differences is a major challenge.